Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(13 sites)
United States
Michael G Oefelein Clinical Trials ( Site 0053), Bakersfield, California Moffitt Cancer Center ( Site 0057), Tampa, Florida Northwestern University ( Site 0051), Chicago, Illinois Johns Hopkins University ( Site 0055), Baltimore, Maryland Canada
Princess Margaret Cancer Centre ( Site 0003), Toronto, Ontario CIUSSS de l'Estrie-CHUS ( Site 0002), Sherbrooke, Quebec France
Hôpital Claude Huriez ( Site 0012), Lille, Nord HENRI MONDOR HOSPITAL ( Site 0011), Créteil, Val-de-Marne Gustave Roussy ( Site 0013), Villejuif, Val-de-Marne Netherlands
Erasmus Medisch Centrum ( Site 0032), Rotterdam, South Holland Spain
Hospital Universitario Virgen de la Victoria ( Site 0043), Málaga, Andalusia Hospital Universitario 12 de Octubre ( Site 0042), Madrid United Kingdom
St Bartholomew s Hospital ( Site 0061), London, London, City of